Request for Information for CPE CBRND for JETT.docx
DOCX document 29 KB Posted
- Solicitation number
- W911SR-26-R-CBRN
About this file
This is a Request for Information (RFI) issued by the Joint Project Manager (JPM) for CBRN Medical under the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), a component of the Department of the Army Materiel Command Army Contracting Command Aberdeen Proving Ground. The RFI (W911SR-26-R-CBRN) serves as market research to assess industry capabilities for developing a ruggedized, military-standard-compliant device capable of delivering nalmefene via both inhalation/intranasal and intramuscular routes of administration for both prophylactic and therapeutic purposes. The device must be designed as a single unit to meet eventual U.S. Food and Drug Administration (FDA) approval as both a therapeutic and prophylactic medical device. Responses are due no later than 12:00 PM ET on Friday, 3 April 2026, submitted through the JETT portal.
Respondents are requested to provide white papers, concept briefs, and technical insights not exceeding five pages, plus one page of past performance documentation. Ideal submissions should include technical descriptions of proposed approaches (with summaries of prior studies), relevant experience and past performance, estimated development timelines and scalability assessments, sustainment considerations, potential cost drivers, and identified risk factors related to development, FDA licensure, and fielding. This RFI is issued solely for information and planning purposes and does not constitute a commitment to issue a future solicitation or contract. All submitted information is voluntary, and the Government will not compensate respondents for participation. Non-response to this RFI will not preclude participation in any future Request for Proposal or Request for Quote, should one be issued.
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Request for Information
W911SR-26-R-CBRN
Title: CPE CBRND Seeking Device Capable of Delivering Medical Countermeasure via Inhalation and Intramuscular Routes THIS IS A REQUEST FOR INFORMATION (RFI) ONLY – This RFI is issued solely for market research, information, and planning purposes – it does not constitute a Request for Proposal (RFP)/Request for Quote (RFQ) or a promise to issue an RFP/RFQ in the future. Solicitations are not available at this time. Requests for a solicitation will not receive a response. This notice does not constitute a commitment by the United States Government to contract for any supply or service whatsoever. All information submitted in response to this announcement is voluntary; the United States Government will not pay for information requested nor will it compensate any respondent for any cost incurred in developing information provided to the United States Government. Not responding to this RFI does not preclude participation in any future RFP/RFQ, if any is issued.
The Joint Project Manager (JPM) for CBRN Medical, under the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), serves as the Department of War’s (DoW) premier program management office for the development and acquisition of safe, effective, and innovative medical solutions to combat Chemical, Biological, Radiological and Nuclear (CBRN) threats to service members. JPM CBRN Medical leads medical countermeasure (MCM) development for vaccines, diagnostics, and therapeutics, which are critical elements to an integrated-layered defense strategy.
The focus of this RFI is to survey current industry capabilities in the development, testing, and manufacturing of devices capable of delivering nalmefene via both inhalation (INH)/intranasal (IN) and intramuscular (IM) routes of administration for both prophylactic and therapeutic purposes. This RFI aims to identify innovative solutions and assess the readiness of industry partners to address emerging operational needs effectively. This market research will also explore alternative methods to deliver both prophylactic and therapeutic MCMs in one device. Technologies must meet the following requirements:
· The device intended for IM and IN/INH delivery must be ruggedized and compliant with military (MIL) standards.
· A single device must be designed to meet the requirements for eventual U.S. Food and Drug Administration (FDA) approval as both a therapeutic and prophylactic product and a medical device.
Responses to this RFI are requested no later than 12:00 PM ET Friday, 3 April 2026
Please respond to this RFI with the following details of your system's capability:
White papers, concept briefs, and technical insights that detail the design feasibility, integration paths, operational readiness, and sustainment strategies for any solutions capable of meeting the above criteria. Summaries of studies performed to date would be beneficial. Submissions should be no more than five (5) pages. Past performances should be no more than one page.
Ideal responses will include:
A technical description of the proposed approach (discussion of studies performed to date would be beneficial), a summary of relevant experience or past performance (no more than one (1) page), estimated timelines and scalability, identified sustainment considerations, potential cost drivers, and risk factors for development, FDA licensure, and fielding.
Please visit the JETT page and select “Respond to an RFI” to share your capability with us. https://jacks.jpeocbrnd.army.mil/JETT
File details come from the government source that posted it. Updated .